R Contains Benzene Ring Patents (Class 514/617)
  • Publication number: 20100183690
    Abstract: Disclosed embodiments include a textile with insect repellent properties comprising (a) a natural or synthetic fabric, (b) a microencapsulated active ingredient having insect repellent properties, and (c) a resin solution to attach said microencapsulated active ingredients to the fabric. According to a particular embodiment, and without limitation, the insect repellent textile uses a resin solution with a concentration designed to control the degree of wash fastness and gradual release of the microencapsulated active ingredient embedded in the textile in order for it to be gradually released by skin pressure and friction. A plurality of microencapsulated active ingredients could be used including microencapsulated permethrin or toluamide.
    Type: Application
    Filed: January 18, 2010
    Publication date: July 22, 2010
    Applicant: INNOVATEC SL
    Inventors: JAIME GISBERT PAYA, MARIA ANGELES BONET ARACIL, PEDRO MATEO RIOBO ABOY, PABLO MONLLOR PEREZ
  • Publication number: 20100172993
    Abstract: The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms.
    Type: Application
    Filed: August 10, 2007
    Publication date: July 8, 2010
    Inventors: Amarjit Singh, Sarabjit Singh, Paramjit Singh, Rajesh Jain
  • Publication number: 20100168084
    Abstract: Methods of using compounds that are HAT inhibitors are described herein.
    Type: Application
    Filed: May 8, 2009
    Publication date: July 1, 2010
    Inventors: L. Julie Huber, Thomas E. McDonagh
  • Patent number: 7745662
    Abstract: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: June 29, 2010
    Assignee: Polymedix, Inc.
    Inventor: Mousa Shaker
  • Patent number: 7737175
    Abstract: The present invention provides methods and compositions for modulating HDAC4 activity and modulating the activity of proteins downstream of HDAC4 in the muscle transcriptional pathway in a cell by modulating HDAC4 activity. Further provided are methods and compositions for treating muscle atrophy and/or inflammation by inhibiting HDAC4 activity.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: June 15, 2010
    Assignee: Duke University
    Inventors: Tso-Pang Yao, Todd Cohen, Tomasa Barrientos De Renshaw
  • Publication number: 20100144778
    Abstract: The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: June 26, 2006
    Publication date: June 10, 2010
    Inventors: Subharekha Raghavan, Steven L. Colletti, Fa-Xiang Ding, Hong Shen, James R. Tata, Ashley Rouse Lins, Abigail Lee Smenton, Weichun Chen, Darby Rye Schmidt, George Scott Tria
  • Publication number: 20100144876
    Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C?—C—(CH2)2CO2H, meta-C?—C—(CH2)2OH, meta-C?C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C?
    Type: Application
    Filed: February 18, 2010
    Publication date: June 10, 2010
    Applicant: UNIVERSITY COLLEGE LONDON
    Inventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce
  • Publication number: 20100137401
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Application
    Filed: February 2, 2010
    Publication date: June 3, 2010
    Applicant: Incyte Corporation
    Inventors: Wenqing Yao, Colin Zhang, Jincong Zhuo, Meizhong Xu, Konstantinos Agrios, Brian Metcalf
  • Patent number: 7723391
    Abstract: Compounds of the formula: wherein Ar1, Ar2, R1 and R2 are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: May 25, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Daisy Joe Du Bois, David Garrett Loughhead, Hans Maag, Jason Manka, David Bernard Smith, David Nigel Hurst
  • Patent number: 7709478
    Abstract: The present invention relates to compounds according to the general formula (I), wherein R1-R4 have the meanings given in the description, A is CH2, CHOH or CH—(C1-C3-alkyl), B, C and D are independently CH2 or CH—(C1-C3-alkyl), and R5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: May 4, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Hartmut Strobel, Paulus Wohlfart
  • Patent number: 7709523
    Abstract: ?-Aminoamide derivatives useful as antimigraine agents, particularly for the treatment of head pain conditions such as migraine, cluster headache or other severe headache, are disclosed. The antimigraine agents of the invention are able to reduce or even stop the pain deriving from such conditions without, virtually, any side effects.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: May 4, 2010
    Assignee: Newron Pharmaceuticals SpA
    Inventors: Patricia Salvati, Marcello Calabresi, Luciano Dho, Orietta Veneroni, Piero Melloni
  • Patent number: 7705031
    Abstract: The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: April 27, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean M. Wilson, Andreas P. Termin, Jesus E. Gonzalez, III, Nicole Zimmermann, Yulian Zhang, Lev T. D. Fanning
  • Patent number: 7705044
    Abstract: The invention relates to compounds of the general formula and optionally the enantiomers thereof. These compounds have advantageous pesticidal properties. They are especially suitable for controlling parasites in warm-blooded animals.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: April 27, 2010
    Assignee: Novartis AG
    Inventors: Pierre Ducray, Jacques Bouvier, Matthias Keller, Corina Bergamin
  • Patent number: 7705053
    Abstract: To provide compounds which have high angiogenesis inhibiting activity, and are useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, for example, cancer and cancer metastasis, methods for producing the compounds, intermediate compounds useful for their production, and pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: December 27, 2004
    Date of Patent: April 27, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroshi Koyano, Atsushi Suda, Kousuke Aso, Kihito Hada, Miyuki Asai, Masami Hasegawa, Yasuko Sato
  • Patent number: 7705182
    Abstract: This invention provides androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: April 27, 2010
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Mitchell S. Steiner, Karen A. Veverka, Dong Jin Hwang, Jiyun Chen
  • Publication number: 20100093733
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts and esters thereof, are useful for the treatment of obesity, type II diabetes and the metabolic syndrome.
    Type: Application
    Filed: February 15, 2008
    Publication date: April 15, 2010
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Graham Dawson, William Gattrell, Martin James Procter, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Philippe Wong-Kai-In
  • Publication number: 20100093707
    Abstract: The present invention relates to an acid amid derivative of the formula (I) or a salt thereof: wherein A is phenyl which may be substituted by X, benzyl which may be substituted by X, naphthyl which may be substituted by X, a heterocyclic group which may be substituted by X, a fused heterocyclic group which may be substituted by X, indanyl (the indanyl may be substituted by halogen, alkyl or alkoxy) or tetrahydronaphthyl (the tetrahydronaphthyl may be substituted by halogen, alkyl or alkoxy), B is alkyl, cycloalkyl, phenyl which may be substituted by Y, a heterocyclic group which may be substituted by Y, or a condensed heterocyclic group which may be substituted by Y, each of R1 and R2 is alkyl, cyano or —CO2R14, or R1 and R2 may together form a 3- to 6-membered saturated carbocyclic ring, R3 is hydrogen, alkyl, alkoxyalkyl, alkylthioalkyl, —COR15, —S(O)mR16 or —S(O)nNR17R18, which is useful as an active ingredient of pesticides.
    Type: Application
    Filed: December 17, 2009
    Publication date: April 15, 2010
    Applicant: ISHIHARA SANGYO KAISHA, LTD.
    Inventors: Yuji NAKAMURA, Masayuki Morita, Tetsuo Yoneda, Kenji Izakura
  • Publication number: 20100087532
    Abstract: A polypeptide is identified as being functionally included in a signal transduction pathway having a biological effect. Contemplated polypeptides are different from a retinoic acid receptor, a retinoid X receptor, or a cellular retinoic acid binding protein, however bind a retinoid or retinoid metabolite, and binding of the retinoid or retinoid metabolite lead to a modulation of the biological effect. In particularly contemplated methods, a retinoid or retinoid metabolite is administered to a cell or mammal in a concentration effective to modulate the biological effect.
    Type: Application
    Filed: September 25, 2009
    Publication date: April 8, 2010
    Inventor: Gerhart GRAUPNER
  • Publication number: 20100087480
    Abstract: This invention provides a compound of the formula (I). These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.
    Type: Application
    Filed: October 11, 2007
    Publication date: April 8, 2010
    Inventors: Koji Ando, Hirotaka Tanaka
  • Publication number: 20100087496
    Abstract: This invention relates to novel cinnamic amide derivatives that are found to be potent modulators of ion channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to modulation of ion channels.
    Type: Application
    Filed: December 17, 2007
    Publication date: April 8, 2010
    Applicant: NeuroSearch A/S
    Inventors: Antonio Nardi, Morten Grunnet, Joachim Demnitz, Thomas Diness Jensen, Palle Christophersen, David Spencer Jones, Elsebet Ostergaard Nielsen, Dorte Strobaek, Lars Siim Madsen
  • Patent number: 7687665
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: March 30, 2010
    Assignee: Incyte Corporation
    Inventors: Wenqing Yao, Colin Zhang, Jincong Zhuo, Meizhong Xu, Konstantinos Agrios, Brian Metcalf
  • Publication number: 20100076084
    Abstract: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic t
    Type: Application
    Filed: November 24, 2009
    Publication date: March 25, 2010
    Inventors: Marjorie Regan Gatlin, Michele Ann Ball, Richard Owen Mannion, Anees Abdulquadar Karnachi, Christiane Guitard, Malcolm Allison
  • Publication number: 20100076078
    Abstract: Novel compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.
    Type: Application
    Filed: September 7, 2007
    Publication date: March 25, 2010
    Applicant: SYNGENTA CORP PROTECTION, INC.
    Inventors: Pierre Jung, Stephen Trah, Christopher Richard Ayles Godfrey, William Lutz, Peter Maienfisch, Werner Zambach
  • Publication number: 20100069454
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for treating, immuno-allergical diseases, autoimmune diseases, and organ or tissue rejection following transplantation.
    Type: Application
    Filed: August 21, 2009
    Publication date: March 18, 2010
    Applicant: Novaremed Limited
    Inventor: Eliahu Kaplan
  • Publication number: 20100069447
    Abstract: Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are defined as provided herein.
    Type: Application
    Filed: October 20, 2009
    Publication date: March 18, 2010
    Inventors: Jay P. POWERS, Michael Degraffenreid, Xiao He, Lisa Julian, Dustin L. McMinn, Daqing Sun, Yosup Rew, Xuelei Yan
  • Publication number: 20100063155
    Abstract: A compound of general formula (I): Also disclosed is a process for preparing this compound, a fungicidal composition comprising a compound of general formula (I), as well as a method for treating plants by applying a compound of general formula (I) or a composition comprising it.
    Type: Application
    Filed: February 21, 2008
    Publication date: March 11, 2010
    Inventors: Pierre-Yves Coqueron, Marie-Claire Grosjean-Cournoyer, Darren James Mansfield, Benoit Hartmann, Klaus Kunz, Ruediger Fischer, Oliver Gaertzen, Amos Mattes, Oswald Ort
  • Patent number: 7674829
    Abstract: The present invention provides methods for treating Acquired Immunodeficiency Syndrome (AIDS) and other viral diseases and Human Immunodeficiency Virus (HIV) related infections by administering one or more compounds of formula I: wherein: the dotted line represents a single or a double bond; and R1 and R2 are the same or different and independently of each other represent —CH2OH, —CH2OR4, —CH(OH)CH3, —CH(OR4)CH3 or a group represented by the formula: or salts or hydrates thereof in a carrier which minimizes micellar formation or van der Waals attraction of molecules of said compound. The invention also provides S enantiomeric forms of such compounds which possess the ability to inhibit cell growth whilst being of low toxicity to such cells and methods of making such compounds.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: March 9, 2010
    Assignee: Novaremed Limited
    Inventor: Eliahu Kaplan
  • Publication number: 20100056444
    Abstract: NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time.
    Type: Application
    Filed: October 11, 2007
    Publication date: March 4, 2010
    Inventors: Sven Martin Jacobson, Robert Ang
  • Publication number: 20100056637
    Abstract: The present invention provides methods of treating or preventing asthma or an inflammatory disease. In one embodiment, the invention provides compounds and formulations for the treatment of asthma or an inflammatory disease.
    Type: Application
    Filed: September 18, 2009
    Publication date: March 4, 2010
    Applicant: Icagen, Inc.
    Inventors: Neil A. Castle, Gregory C. Rigdon, Douglas S. Krafte, Jeffrey L. Krajewski
  • Publication number: 20100056636
    Abstract: The present invention relates to substances and compositions having a physiological cooling effect on the skin and the mucosa of the body, especially of the oral cavity, throat and nose. More in particular, the present invention relates to N-substituted-p-menthane-3-carboxamides represented by the following formula (I): and esters thereof. These substances are capable of imparting and/or enhancing a physiological cooling effect in a product in which they are incorporated, much more effectively than the heretofore known N-substituted-p-menthane-3-carboxamides.
    Type: Application
    Filed: November 30, 2007
    Publication date: March 4, 2010
    Inventors: Stefan Michael Furrer, Sander Tondeur, Chris Winkel, Harry Renes, Adri De klerk
  • Publication number: 20100041715
    Abstract: The invention provides certain well-defined benzamides that are useful as sphingosine-1-phosphate antagonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: August 12, 2009
    Publication date: February 18, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Phong X. Nguyen, Todd M. Heidelbaugh, Ken Chow
  • Publication number: 20100041762
    Abstract: The invention relates to compounds of structural formula (I) or (II): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein L, L1, Y, R1, R2, R9, R10, ring A, ring B, ring C, and ring D are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: August 14, 2009
    Publication date: February 18, 2010
    Applicant: Synta Pharmaceuticals Corporation
    Inventors: Gary Bohnert, Shoujun Chen
  • Patent number: 7662860
    Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: February 16, 2010
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Lead Discovery Pharmaceuticals Limited Company
    Inventors: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye
  • Publication number: 20100029776
    Abstract: A composition comprising fenamidone (a) and an insecticide compound (b) in a (a)/(b) weight ratio of from 1/1000 to 1000/1. A composition further comprising an additional fungicidal compound.
    Type: Application
    Filed: December 21, 2007
    Publication date: February 4, 2010
    Applicant: BAYER CROP SCIENCE AG
    Inventors: Heike Hungenberg, Wolfgang Thielert, Koen Van Den Eynde
  • Publication number: 20100029662
    Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
    Type: Application
    Filed: July 27, 2009
    Publication date: February 4, 2010
    Inventor: Gerald Horn
  • Publication number: 20100029663
    Abstract: The invention generally relates to compositions and methods for reducing activation of a-1 adrenergic receptors. The compositions comprise highly selective a-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
    Type: Application
    Filed: July 27, 2009
    Publication date: February 4, 2010
    Inventor: Gerald Horn
  • Publication number: 20100029777
    Abstract: Analogs of 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid and methods of manufacture and use thereof, such as for use in cancer prevention and treatment.
    Type: Application
    Filed: July 31, 2009
    Publication date: February 4, 2010
    Inventors: Robert W. Curley, JR., Margaret Clagett-Dame, Michael D. Collins, Victoria V. Abzianidze
  • Publication number: 20100028348
    Abstract: The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as heart failure.
    Type: Application
    Filed: September 17, 2009
    Publication date: February 4, 2010
    Applicant: MITOTEK, LLC
    Inventor: Paul Q. Anziano
  • Publication number: 20100029567
    Abstract: Compounds, methods, uses, compositions, kits and packages for the treatment of imbalance between bone resorption and bone formation, based on uses of 4-phenyl-2 propionamidotetralin (4-P-PDOT) and analogs, derivatives, prodrugs, precursors thereof, and salts thereof, are described.
    Type: Application
    Filed: February 15, 2008
    Publication date: February 4, 2010
    Applicant: CHU SAINTE-JUSTINE
    Inventors: Alain Moreau, Genevieve Mailhot
  • Publication number: 20100029660
    Abstract: The invention generally relates to compositions and methods for inducing vasoconstriction with low incidence of rebound hyperemia. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
    Type: Application
    Filed: July 27, 2009
    Publication date: February 4, 2010
    Inventor: Gerald Horn
  • Publication number: 20100022547
    Abstract: One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition of C. parvum inosine-5?-monophosphate-dehydrogenase over human inosine-5?-monophosphate-dehydrogenase (IMPDH type I and type II). These compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.
    Type: Application
    Filed: June 1, 2007
    Publication date: January 28, 2010
    Applicants: BRANDEIS UNIVERSITY, UNIVERSITY OF GEORFIA RESEARCH FOUNDATION
    Inventors: Lizbeth K. Hedstrom, Boris Striepen
  • Publication number: 20100016252
    Abstract: Disclosed are Mannich base N-oxides of drugs containing acidic N—H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one or more other active agents or treatments.
    Type: Application
    Filed: September 21, 2009
    Publication date: January 21, 2010
    Applicant: State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U
    Inventors: John F.W. Keana, Paul Westberg, John Curd, Alshad S. Lalani
  • Publication number: 20100016374
    Abstract: Compounds of formula (I) and salts and solvates are provided: wherein R2 is selected from phenyl substituted with n R1 groups, and pyridyl substituted with n R1 groups; n=0, 1 or 2; each R1 is independently selected from the group consisting of halo, C1-4alkyl, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy and cyano; R3 is selected from hydrogen and C1-2 alkyl; R4 is selected from the group consisting of ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl; or R3 and R4 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocyclic ring optionally substituted with one or more groups X; each X is independently selected from the group consisting of C1-4alkyl, and haloC1-4alkyl; R12 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl and methylthio; R13 is selected from hydrogen, chloro and trifluoromethyl; R14 is selected from hydrogen, trifluoromethyl and chloro; R15 is selected from hydrogen, chloro and trifluoromethyl; R16 is selected
    Type: Application
    Filed: April 3, 2007
    Publication date: January 21, 2010
    Inventors: Steven Coulton, Martin Gilpin, Roderick Alan Porter
  • Publication number: 20100016291
    Abstract: The present invention is concerned with novel tetrahydro-naphthalene-1-carboxylic acid derivatives having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes. Formula (I).
    Type: Application
    Filed: October 22, 2007
    Publication date: January 21, 2010
    Inventors: Lieven Meerpoel, Leo Jacobus Jozef Backx, Peter Ten Holte, Guuske Frederike Busscher
  • Publication number: 20100008976
    Abstract: The invention relates to compounds having the general structural formula (formula I) for use in a diagnostic method or a method for treatment of the human or animal body by surgery or therapy.
    Type: Application
    Filed: July 16, 2007
    Publication date: January 14, 2010
    Applicant: Westfallsche Wilheims Universitat Munster
    Inventors: Andreas Hensel, Thomas Hofmann, Alexandra Deters, Timo Stark
  • Patent number: 7645905
    Abstract: Crystalline form IV of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: January 12, 2010
    Assignee: Les Laboratoires Servier
    Inventors: Gerard Coquerel, Julie Linol, Jean-Claude Souvie
  • Publication number: 20100004244
    Abstract: The present invention relates to ligands of the peripheral cannabinoid receptor CB2, especially (+)-?-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for promoting, inducing and enhancing neurogenesis including neural cell regeneration. In particular, pharmaceutical compositions of the invention will be useful for preventing, alleviating or treating neurological injuries or damages to the CNS or the PNS associated with physical injury, ischemia, neurodegenerative disorders, certain medical procedures or medications, tumors, infections, metabolic or nutritional disorders, cognition or mood disorders, and various medical conditions associated with neural damage or destruction.
    Type: Application
    Filed: June 27, 2007
    Publication date: January 7, 2010
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Ismael Galve-Roperh, Manuel Guzman, Raphael Mechoulam, Javier Palazuelos, Tania Aguado
  • Patent number: 7642290
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for treating, immuno-allergical diseases, autoimmune diseases, and organ or tissue rejection following transplantation.
    Type: Grant
    Filed: October 1, 2003
    Date of Patent: January 5, 2010
    Assignee: Novaremed Limited
    Inventor: Eliahu Kaplan
  • Patent number: 7642379
    Abstract: The invention relates to compounds of the general formula (I) wherein Ar, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, W, a, b, m, n, o and p are as defined in claim 1, and to any enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are particularly suitable for controlling parasites in warm-blooded animals.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: January 5, 2010
    Assignee: Novartis AG
    Inventors: Noëlle Gauvry, Pierre Ducray, Thomas Goebel, Ronald Kaminsky
  • Publication number: 20090311188
    Abstract: In vitro and in vivo methods for identifying compounds capable of targeting suppressed cancer cells such as micrometastatic cells. The in vitro method includes the steps of comparing the response to a test compound of cancer cells grown on a suppressing cell support matrix which causes suppression of a malignant phenotype in a growing cancer cell and on a non-suppressing cell support matrix. The in vivo method includes a step of co-injecting labeled cancer cells with a malignant-phenotype suppressing matrix into a test animal to produce suppressed micrometastatic cells therein.
    Type: Application
    Filed: August 13, 2009
    Publication date: December 17, 2009
    Inventors: Robert E. Hurst, Michael A. Ihnat